ReviewNature reviews. Gastroenterology & hepatology2009
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer.
Review in Nature reviews. Gastroenterology & hepatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 1 synthesis or guideline pooled it, 271 citations in OpenAlex.
- KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.Oncotarget · 2017Pooled it
- Theabrownin combined with zearalenone suppresses colitis-associated colorectal cancer by inhibiting PI3K/AKT pathway and enhancing microbial propionate production.Scientific reports · 2025Article
- Colorectal Cancer and Inflammatory Bowel Disease.Clinics in colon and rectal surgery · 2025Review
- The Cross-talk of Non-coding RNAs and Inflammation in Human Cancer.Current pharmaceutical biotechnology · 2025Review
- Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link.International journal of colorectal disease · 2024Review
- A New Combination ofFoods (Basel, Switzerland) · 2024Article
- Therapeutic potential of Pien Tze Huang in colitis-associated colorectal cancer: mechanistic insights from a mouse model.Cancer cell international · 2024Article
- Disruption of hypoxia-inducible factor-2α in neutrophils decreases colitis-associated colon cancer.American journal of physiology. Gastrointestinal and liver physiology · 2024Article
- The association between inflammatory bowel disease and all-cause and cause-specific mortality in the UK Biobank.Annals of epidemiology · 2023Article
- Article
- Phosphorylation of PPDPF via IL6-JAK2 activates the Wnt/β-catenin pathway in colorectal cancer.EMBO reports · 2023Article
- Review
- Pathways Related to Colon Inflammation Are Associated with Colorectal Carcinoma: A Transcriptome- and Methylome-Wide Study.Cancers · 2023Article
- Fructose-1,6-bisphosphatase 1 dephosphorylates IκBα and suppresses colorectal tumorigenesis.Cell research · 2023Article
- Uncoupled nitric oxide synthase activity promotes colorectal cancer progression.Frontiers in oncology · 2023Article
- Prognostic value of primary tumor sidedness in patients with non-metastatic IBD related CRC - Is it the exception to the rule?Surgical oncology · 2022Article
- Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease.Gut and liver · 2022Review
- Neuropeptide Y, a paracrine factor secreted by cancer cells, is an independent regulator of angiogenesis in colon cancer.British journal of cancer · 2022Article
- Colitis-associated intestinal microbiota regulates brain glycine and host behavior in mice.Scientific reports · 2022Article
- Pou3f1 mediates the effect of Nfatc3 on ulcerative colitis-associated colorectal cancer by regulating inflammation.Cellular & molecular biology letters · 2022Article
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with IBD, chronic colonic inflammation increases the risk of colorectal cancer, perhaps because inflammation predisposes these tissues to genomic instability. Carcinogenesis in the inflamed colon seems to follow a different sequence of genetic alterations than that observed in sporadic cancers in the uninflamed colon. In this Review, we focus on the genetic alterations in colitis-associated colorectal cancer that contribute to the acquisition of the essential hallmarks of cancer, and on how those alterations differ from sporadic colorectal cancers. Our intent is to provide a conceptual basis for categorizing carcinogenetic molecular abnormalities in IBD, and for understanding how cancer-preventive therapies might target reversal of acquired abnormalities in specific biochemical pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.